Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Jenna L. Carter, Katie Hege, Jay Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 165

Showing 1-25 of 165 citing articles:

Advances in acute myeloid leukemia
Laura F. Newell, Rachel J. Cook
BMJ (2021), pp. n2026-n2026
Open Access | Times Cited: 310
Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
Maike Janssen, Christina Schmidt, Peter‐Martin Bruch, et al.
Blood (2022) Vol. 140, Iss. 24, pp. 2594-2610
Open Access | Times Cited: 62
Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia
Bryann Pardieu, Justine Pasanisi, Frank Ling, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1585-1595
Open Access | Times Cited: 48
The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways
Maryam Bakhtiyari, Mahsa Liaghat, Fatemeh Aziziyan, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 30
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Azadeh C. Bashi, Elizabeth A. Coker, Krishna C. Bulusu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 846-865
Open Access | Times Cited: 12
ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress
Jenna L. Carter, Yongwei Su, Eman T. Al‐Antary, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Innovative laboratory techniques shaping cancer diagnosis and treatment in developing countries
Azeez Okikiola Lawal, Tolulope Joseph Ogunniyi, Oriire Idunnuoluwa Oludele, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia
Xiaoyan Hu, Lin Li, Jewel Nkwocha, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Targeting of the tumor microenvironment by curcumin
Xiao Fu, Yingni He, Mu Li, et al.
BioFactors (2021) Vol. 47, Iss. 6, pp. 914-932
Closed Access | Times Cited: 51
The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia
Esraa M. Othman, Eman A. Fayed, Ebtehal M. Husseiny, et al.
Bioorganic Chemistry (2022) Vol. 127, pp. 105968-105968
Closed Access | Times Cited: 37
Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions
Hongguang Deng, Yu Han, Liang Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 5963-5998
Closed Access | Times Cited: 8
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia
Zhiyu Zhang, Jiayi Huang, Zhibo Zhang, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML
Diana Macečková, Lenka Vaňková, Monika Holubová, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 7
Licochalcone A induces mitochondria-dependent apoptosis and interacts with venetoclax in acute myeloid leukemia
Youhong Li, Mengting Zhao, Lin Ye, et al.
European Journal of Pharmacology (2024) Vol. 968, pp. 176418-176418
Closed Access | Times Cited: 6
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemia
Ellen Madarang, Jill Lykon, Wei Zhao, et al.
Deleted Journal (2024) Vol. 1, Iss. 2, pp. 100016-100016
Open Access | Times Cited: 6
Natural isoflavonoids in invasive cancer therapy: From bench to bedside
Lorena Cayetano‐Salazar, Monserrat Olea‐Flores, Miriam D. Zuñiga‐Eulogio, et al.
Phytotherapy Research (2021) Vol. 35, Iss. 8, pp. 4092-4110
Closed Access | Times Cited: 37
Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives
Ian M. Bouligny, Keri Maher, Steven Grant
Blood Reviews (2022) Vol. 57, pp. 100996-100996
Open Access | Times Cited: 28
The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting
Olivia L. Walker, Margaret L. Dahn, Melanie R. Power Coombs, et al.
Frontiers in Oncology (2022) Vol. 11
Open Access | Times Cited: 26
Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine
Pedro Casado, Pedro R. Cutillas
Molecular & Cellular Proteomics (2023) Vol. 22, Iss. 4, pp. 100517-100517
Open Access | Times Cited: 16
MDFI promotes the proliferation and tolerance to chemotherapy of colorectal cancer cells by binding ITGB4/LAMB3 to activate the AKT signaling pathway
Ding Ma, Shuwen Liu, Kua Liu, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Targeting BMAL1 reverses drug resistance of acute myeloid leukemia cells and promotes ferroptosis through HMGB1-GPX4 signaling pathway
Hong Zheng, Ting Wu, Zhi Lin, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access | Times Cited: 5
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation
Pengyun Li, Xiaotong Hu, Zhiya Fan, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 5
Human mesenchymal stem cells derived exosomes inhibit the growth of acute myeloid leukemia cells via regulating miR-23b-5p/TRIM14 pathway
Hui Cheng, Jie Ding, Gusheng Tang, et al.
Molecular Medicine (2021) Vol. 27, Iss. 1
Open Access | Times Cited: 27
A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia
Taku Harada, Yaser Heshmati, Jérémie Kalfon, et al.
Genes & Development (2022) Vol. 36, Iss. 5-6, pp. 368-389
Open Access | Times Cited: 20
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML
Maike Roas, Binje Vick, Marc‐André Kasper, et al.
Blood (2022) Vol. 141, Iss. 9, pp. 1023-1035
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top